That's why OpenAI's push to own the developer ecosystem end-to-end matters in26. "End-to-end" here doesn't mean only better models. It means the ...
EGFR-targeted therapy is often used in patients with EGFR-driven cancer but is limited by on-target/off-tumor toxicities. Here, the authors develop a bispecific antibody targeting both EGFR and B7-H3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results